187 related articles for article (PubMed ID: 33918641)
1. Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma.
Hsu FT; Liu YC; Tsai CL; Yueh PF; Chang CH; Lan KL
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918641
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma.
Hsu FT; Tsai CL; Chiang IT; Lan KH; Yueh PF; Liang WY; Lin CS; Chao Y; Lan KL
J Cell Mol Med; 2022 Apr; 26(7):1955-1968. PubMed ID: 35174623
[TBL] [Abstract][Full Text] [Related]
3. SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy.
Cini JK; Dexter S; Rezac DJ; McAndrew SJ; Hedou G; Brody R; Eraslan RN; Kenney RT; Mohan P
Front Immunol; 2023; 14():1326927. PubMed ID: 38250068
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy.
Fukushima H; Furusawa A; Kato T; Wakiyama H; Takao S; Okuyama S; Choyke PL; Kobayashi H
Mol Cancer Ther; 2023 Oct; 22(10):1215-1227. PubMed ID: 37461129
[TBL] [Abstract][Full Text] [Related]
5. A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells.
Li Y; Wu L; Liu Y; Ma S; Huang B; Feng X; Wang H
Transl Oncol; 2022 Jul; 21():101424. PubMed ID: 35477065
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
7. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
D'Alterio C; Buoncervello M; Ieranò C; Napolitano M; Portella L; Rea G; Barbieri A; Luciano A; Scognamiglio G; Tatangelo F; Anniciello AM; Monaco M; Cavalcanti E; Maiolino P; Romagnoli G; Arra C; Botti G; Gabriele L; Scala S
J Exp Clin Cancer Res; 2019 Oct; 38(1):432. PubMed ID: 31661001
[TBL] [Abstract][Full Text] [Related]
8. Enhanced half-life and antitumor activity of interleukin-15 through genetic fusion of a serum albumin-specific protein binder.
Kim D; Park JH; Kim TY; Kim DG; Byun JH; Kim HS
Int J Pharm; 2022 Sep; 625():122059. PubMed ID: 35905933
[TBL] [Abstract][Full Text] [Related]
9. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
10. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using
Liechtenstein T; Perez-Janices N; Blanco-Luquin I; Goyvaerts C; Schwarze J; Dufait I; Lanna A; Ridder M; Guerrero-Setas D; Breckpot K; Escors D
Oncoimmunology; 2014; 3(7):e945378. PubMed ID: 25954597
[TBL] [Abstract][Full Text] [Related]
11. Synergistic cancer immunotherapy utilizing programmed Salmonella typhimurium secreting heterologous flagellin B conjugated to interleukin-15 proteins.
Zhang Y; Tan W; Sultonova RD; Nguyen DH; Zheng JH; You SH; Rhee JH; Kim SY; Khim K; Hong Y; Min JJ
Biomaterials; 2023 Jul; 298():122135. PubMed ID: 37148758
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.
Fallon JK; Vandeveer AJ; Schlom J; Greiner JW
Oncotarget; 2017 Mar; 8(13):20558-20571. PubMed ID: 28423552
[TBL] [Abstract][Full Text] [Related]
13. M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.
Knudson KM; Hicks KC; Luo X; Chen JQ; Schlom J; Gameiro SR
Oncoimmunology; 2018; 7(5):e1426519. PubMed ID: 29721396
[TBL] [Abstract][Full Text] [Related]
14. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Ye L; Xing Y; Hu J; Xi T
Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
[TBL] [Abstract][Full Text] [Related]
15. Long-term expression of rAAV2-hIL15 enhances immunoglobulin production and lymphokine-activated killer cell-mediated human glioblastoma cell death.
Yiang GT; Chou RH; Chang WJ; Wei CW; Yu YL
Mol Clin Oncol; 2013 Mar; 1(2):321-325. PubMed ID: 24649169
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.
Ng S; Deng J; Chinnadurai R; Yuan S; Pennati A; Galipeau J
Cancer Res; 2016 Oct; 76(19):5683-5695. PubMed ID: 27488533
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice.
Yiang GT; Harn HJ; Yu YL; Hu SC; Hung YT; Hsieh CJ; Lin SZ; Wei CW
J Biomed Sci; 2009 May; 16(1):47. PubMed ID: 19422685
[TBL] [Abstract][Full Text] [Related]
18. Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization.
Sun NY; Chen YL; Wu WY; Lin HW; Chiang YC; Chang CF; Tai YJ; Hsu HC; Chen CA; Sun WZ; Cheng WF
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31546897
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice.
Yiang GT; Chou PL; Tsai HF; Chen LA; Chang WJ; Yu YL; Wei CW
Int J Mol Med; 2012 May; 29(5):809-14. PubMed ID: 22367420
[TBL] [Abstract][Full Text] [Related]
20. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
